PMID- 20629183
OWN - NLM
STAT- MEDLINE
DCOM- 20110512
LR  - 20180913
IS  - 1536-4844 (Electronic)
IS  - 1078-0998 (Linking)
VI  - 17
IP  - 1
DP  - 2011 Jan
TI  - Characterization of patients with infliximab-induced lupus erythematosus and 
      outcomes after retreatment with a second anti-TNF agent.
PG  - 99-104
LID - 10.1002/ibd.21370 [doi]
AB  - BACKGROUND: Drug-induced lupus erythematosus (DILE) due to infliximab therapy for 
      inflammatory bowel disease (IBD) is an uncommon occurrence. It remains uncertain 
      whether patients with infliximab-induced DILE could tolerate another antitumor 
      necrosis factor (TNF) agent without recurrent DILE. METHODS: We reviewed the case 
      records of patients with infliximab-induced DILE diagnosed at our institute and 
      noted details of their clinical and immunological profile at presentation. In 
      addition, case notes of patients who were treated with a second anti-TNF agent 
      were examined for evidence of recurrent DILE. RESULTS: Thirteen patients with 
      infliximab-induced DILE were identified with a female-to-male ratio of 11:2. 
      Symmetric large joint arthralgias and high titers of antinuclear and 
      antidouble-stranded DNA antibody were noted in all patients. Eight patients were 
      retreated with a second anti-TNF agent (six certolizumab pegol and two 
      adalimumab) of whom two patients (one adalimumab and certolizumab pegol each) 
      developed recurrent DILE following 3 months of therapy with a second anti-TNF 
      agent. One patient discontinued therapy after 2 months despite no recurrence of 
      DILE, due to fear of side effects. Five patients remain well with no recurrence 
      of DILE after a median of 5 months (range 2-6) therapy. CONCLUSIONS: Rechallenge 
      with a further anti-TNF agent in patients who have developed DILE with infliximab 
      is associated with a low rate of recurrence.
CI  - Copyright (c) 2010 Crohn's & Colitis Foundation of America, Inc.
FAU - Subramanian, Sreedhar
AU  - Subramanian S
AD  - Department of Gastroenterology, Royal Liverpool University Hospital, Liverpool, 
      UK. sreedhar.subramanian@rlbuht.nhs.uk
FAU - Yajnik, Vijay
AU  - Yajnik V
FAU - Sands, Bruce E
AU  - Sands BE
FAU - Cullen, Garret
AU  - Cullen G
FAU - Korzenik, Joshua R
AU  - Korzenik JR
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Inflamm Bowel Dis
JT  - Inflammatory bowel diseases
JID - 9508162
RN  - 0 (Antibodies, Antinuclear)
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Autoantibodies)
RN  - 0 (Gastrointestinal Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 9007-49-2 (DNA)
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Adult
MH  - Antibodies, Antinuclear/blood/immunology
MH  - Antibodies, Monoclonal/adverse effects/*therapeutic use
MH  - Autoantibodies/immunology
MH  - Cohort Studies
MH  - DNA/blood/immunology
MH  - Female
MH  - Gastrointestinal Agents/adverse effects/*therapeutic use
MH  - Humans
MH  - Infliximab
MH  - Lupus Erythematosus, Systemic/*chemically induced/diagnosis/immunology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - *Secondary Prevention
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors/immunology
EDAT- 2010/07/16 06:00
MHDA- 2011/05/13 06:00
CRDT- 2010/07/15 06:00
PHST- 2010/07/15 06:00 [entrez]
PHST- 2010/07/16 06:00 [pubmed]
PHST- 2011/05/13 06:00 [medline]
AID - 10.1002/ibd.21370 [doi]
PST - ppublish
SO  - Inflamm Bowel Dis. 2011 Jan;17(1):99-104. doi: 10.1002/ibd.21370.